Adverse prognosis of multiple body and 1p/19q common deletion of less protogliolitoplasm

A recent study published in the journal Neuro-oncology, entitled Polysomy is with poor poor outcome in 1p19q co-deleted oligodroglial tumors, demonstrated a negative prognosis associated with the common absence of 1p/19q of less protrusion glioblastoma- Excerpted from the article chapter
(Ref:Neuro Oncol.2019 May 29pii: noz098doi: 10.1093/neuonc/noz098"Epub foreprint"the1p/19q joint co-miss is a molecular marker for the diagnosis of less protoplacytesThe 1p/19q status combined with the mutations of IDH and TERT can be used to evaluate the prognosis of glioma patientsThe state of 1p/19q is also an important molecular marker for clinicians to choose treatment methods and evaluate the efficacy of chemotherapyPatients with 1p/19q combined loss were more sensitive to chemotherapy than patients withno spleusHowever, when USING FISH to detect 1p/19q, we were able to detect the presence of polymers in tumor cells in some patient samples (defined as more than two signals of 1q25 and 19p13)Previous studies have not had sufficient evidence that the presence of polysaccos is associated with the prognosis and survival of gliomasA recent study published in the journal Neuro-oncology, entitled Polysomy is with poor poor outcome in 1p19q co-deleted oligodroglial tumors, demonstrated a negative prognosis associated with the common absence of 1p/19q of less protrusion glioblastomathe study collected tissue samples of 412 tissues with less protoplacytes from eight research institutions and tested them for chromosome1p and 19q status using the FISH platform based on the state of 1p/19q and whether it has a polytobody (defined as having signals greater than 2 1q and 19p in cells) See Figure 1) divided the sampleinto into 4 groups and compared the non-progression lifetime (PFS) and total lifetime (OS) Figure 1:
FISH represents the 1p/19q state of chromosomes and multibody images A 1p/19q occurs with a total loss and does not have a multibody B 1p/19q occurs with a total loss and has a multibody C 1p/19q does not occur with conjuecas and does not have a multibody D 1p/19q does not occur with conjumed deletions and has multiples 412 tissue-typed tissue samples with less protoscoccal glioblastoma were detected in 333 (81%) samples with 1p/19q total missing, 195 (59%) of the samples had multiple bodies at the same time, 138 (41%) of the samples did not have a multibody 79 (19%) samples of chromosome 1p/19q did not have a total deletion, of which 30 (38%) of the samples were present at the same time polymerites, 49 (62%) of the samples did not have polymeras consistent with previous studies, patients with 1p/19q total loss had better PFS and OS (p 0.0001) than those with no missing patients with 1p/19q conjugation and carrying multiples had PFS significantly shorter than patients with only 1p/19q total deletion (p-0.0001), but had longer PFS and OS (p 0.01 and p 0.0001) than patients with 1p/19q non-total loss (Figure 2) the presence of multiple bodies did not affect the prognosis of patients with out-of-the-box loss of 1p/19q tumor patients with more than 30% multibody cells and tumor patients with less than 30% polysocytes had no significant prognosis difference (Figure 3) Figure 2: 1p/19q total missing, carrying multibody patients, 1p/19q total missing, non-carrying multibody patients and 1p/19q did not occur total loss of patients prognosis statistical results Figure 3: 1p/19q did not occur with a prognosis statistic of total deletion and presence of multiple bodies.